Z01 BC010666/ImNIH/Intramural NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2008	4
2009	4
2010	6
2011	9
2012	5
2013	4
2014	2
2015	3
2016	2
2017	3
2018	2
2019	2
2023	1
2025	1

1

Immunotherapy in genitourinary malignancies.

Wattenberg MM, Fong L, Madan RA, Gulley JL. Wattenberg MM, et al. Curr Opin Urol. 2016 Nov;26(6):501-7. doi: 10.1097/MOU.0000000000000331. Curr Opin Urol. 2016. PMID: 27471994 Free PMC article. Review.

2

Immunotherapy of Prostate Cancer: Facts and Hopes.

Bilusic M, Madan RA, Gulley JL. Bilusic M, et al. Clin Cancer Res. 2017 Nov 15;23(22):6764-6770. doi: 10.1158/1078-0432.CCR-17-0019. Epub 2017 Jun 29. Clin Cancer Res. 2017. PMID: 28663235 Free PMC article. Review.

3

PRGN-2012 gene therapy in adults with recurrent respiratory papillomatosis: a pivotal phase 1/2 clinical trial.

Norberg SM, Valdez J, Napier S, Kenyon M, Ferraro E, Wheatley M, Parsons-Wandell L, Doran SL, Lankford A, Sabzevari H, Brough DE, Schlom J, Gulley JL, Allen CT. Norberg SM, et al. Lancet Respir Med. 2025 Apr;13(4):318-326. doi: 10.1016/S2213-2600(24)00368-0. Epub 2025 Jan 21. Lancet Respir Med. 2025. PMID: 39855244 Clinical Trial.

4

Poxviral vectors for cancer immunotherapy.

Kim JW, Gulley JL. Kim JW, et al. Expert Opin Biol Ther. 2012 Apr;12(4):463-78. doi: 10.1517/14712598.2012.668516. Expert Opin Biol Ther. 2012. PMID: 22413824 Free PMC article. Review.

5

Molecular Pathways and Mechanisms of TGFβ in Cancer Therapy.

Barcellos-Hoff MH, Gulley JL. Barcellos-Hoff MH, et al. Clin Cancer Res. 2023 Jun 1;29(11):2025-2033. doi: 10.1158/1078-0432.CCR-21-3750. Clin Cancer Res. 2023. PMID: 36598437 Free PMC article.

6

Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer.

Madan RA, Gulley JL. Madan RA, et al. Expert Rev Vaccines. 2011 Feb;10(2):141-50. doi: 10.1586/erv.10.173. Expert Rev Vaccines. 2011. PMID: 21332262 Free PMC article. Review.

7

Therapeutic vaccines and immunotherapy in castration-resistant prostate cancer: current progress and clinical applications.

Gulley JL, Madan RA, Heery CR. Gulley JL, et al. Am Soc Clin Oncol Educ Book. 2013:10.1200/EdBook_AM.2013.33.e166. doi: 10.14694/EdBook_AM.2013.33.e166. Am Soc Clin Oncol Educ Book. 2013. PMID: 23714490 Free PMC article. Review.

8

Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines.

Bilusic M, Gulley JL. Bilusic M, et al. Cancer Immunol Immunother. 2012 Jan;61(1):109-17. doi: 10.1007/s00262-011-1141-0. Epub 2011 Nov 26. Cancer Immunol Immunother. 2012. PMID: 22120693 Free PMC article. Review.

9

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer.

Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Madan RA, et al. Expert Opin Investig Drugs. 2009 Jul;18(7):1001-11. doi: 10.1517/13543780902997928. Expert Opin Investig Drugs. 2009. PMID: 19548854 Free PMC article. Review.

10

Targeting the immune system in non-small-cell lung cancer: bridging the gap between promising concept and therapeutic reality.

Kelly RJ, Gulley JL, Giaccone G. Kelly RJ, et al. Clin Lung Cancer. 2010 Jul 1;11(4):228-37. doi: 10.3816/CLC.2010.n.029. Clin Lung Cancer. 2010. PMID: 20630824 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Results by year